type 2 diabetes
Conditions
Interventions
pioglitazone 15-30 mg/day
glimepiride 1-4 mg/day
Sponsors
PioRAGE research group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)subjects who had a baseline glycated hemoglobin(HbA1C) level of 6.0 % or more and below 10.0 % 2)subjects who agreed to participate with written informed concent
Exclusion criteria
Exclusion criteria: 1)subjects currently on pioglitazone therapy 2)subjects under treatment with insulin 3)subjects under treatment with glimepiride 3-6 mg/day or gliclazide 80-160 mg/day or glibenclamide 5-10 mg/day 4)subjects with congestive heart failure 5)subjects with liver cirrhosis 6)subjects with renal dysfunction (serum creatinine level is 2.0 mg/dl or more) 7)subjects with malignant diseases or hard to be followed 8)subjects who were judged to be inappropriate for inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum soluble form of receptor for advanced glycation end-products(sRAGE), serum endogenous secretory RAGE(esRAGE) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)surface RAGE expression on isolated peripheral blood mononuclear cells (PBMCs) 2)serum adiponectin, serum fetuin A, serum TNF-related apoptosis-inducing ligand(TRAIL), serum osteoprotegerin(OPG), serum high sensitivity C-reactive protein(hs-CRP) 3)gene expression of PBMCs(RAGE, ADAM10, ADAM17) 4)serum carboxymethyllysine(CML) | — |
Countries
Japan
Contacts
Public ContactShinji Tanaka
Osaka City University Graduate School of Medicine Department of Metabolism, Endocrinology and Molecular Medicine
Outcome results
None listed